1. Japan Stocks

  2. •

    Consumer Defensive

  3. •

    Household & Personal Products
Kobayashi Pharmaceutical Co., Ltd.

Kobayashi Pharmaceutical Co., Ltd.

4967.T
Kobayashi Pharmaceutical Co., Ltd.JP flagTokyo Stock Exchange
5,715.00
JPY
+65.00
- -
424.85BMarket Cap
Kobayashi Pharmaceutical Co., Ltd.
4967.T
(Tokyo Stock Exchange)

Recent

price

5,715.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
1,576.13
1,597.4
1,601.62
1,483.98
1,554.32
1,574.62
1,686.9
1,989.35
2,119.1
2,019.23
1,925.64
1,987.23
2,155.78
2,287.03
2,227.63
2,229.57
1,244.62
Revenue per Share
112.93
113.98
143.18
148.68
150.28
152.72
165.55
201.31
228.04
244.07
245.7
252.35
259.61
268.16
135.42
49.18
116.18
Basic EPS, GAAP
150.6
134.35
185.09
77.74
124.17
144.37
126.41
242.96
206.32
194.92
253.79
233.4
203.38
63.17
-206.93
155.76
- -
Free Cash Flow per Basic Share
28.99
33
34.01
40.99
42.99
43.58
47.17
55.11
60.96
68.01
74
80.01
84.4
95.24
100.96
102.95
- -
Dividend per Share
1,086.74
1,167.73
1,276.95
1,384.63
1,491.9
1,610.98
1,732.7
1,906.19
2,066.31
2,258.47
2,437.48
2,611
2,563.92
2,757.43
2,847.63
2,793.86
2,833.08
Book Value per Share
929.91
1,043.04
1,179.45
1,340.46
1,483.89
1,644.34
1,680.49
1,891.02
2,042.49
2,162.12
2,172.23
2,341.64
2,393.51
2,415.55
2,593.47
2,604.24
2,562.63
Tangible Book Value per Share
82
82
82
82
82
82
81
79
79
78
78
78
77
76
74
74
74
Basic Weighted Avg Shares
129,082
130,824
131,166
121,532
127,293
128,344
137,211
156,761
167,479
158,340
150,514
155,252
166,258
173,455
165,600
165,742
92,464
Sales/Revenue/Turnover
18.38
19.22
14.72
13.91
14.24
13.96
13.31
14.63
15.7
16.21
17.24
16.79
16.04
14.86
15.02
9.01
16.65
Operating Margin (%)
4,256
4,155
3,231
2,969
3,096
3,095
3,071
3,519
3,403
4,127
4,106
4,835
5,358
6,057
8,022
8,745
- -
Depreciation Expense
9,249
9,335
11,726
12,176
12,307
12,448
13,466
15,863
18,023
19,139
19,205
19,715
20,022
20,338
10,067
3,656
8,631
Net Income, GAAP
36.44
29.15
40.84
35.41
37.42
37.93
28.26
29.72
28.77
28.6
27.9
28.66
28.36
26.2
27.61
2.22
25.94
Effective Tax Rate (%)
7.17
7.14
8.94
10.02
9.67
9.7
9.81
10.12
10.76
12.09
12.76
12.7
12.04
11.73
6.08
2.21
9.33
Profit Margin (%)
46,184
54,312
64,747
59,876
71,398
80,100
83,866
88,072
96,771
109,279
114,118
131,186
121,083
102,220
98,045
88,683
89,466
Working Capital
1,149
874
483
163
609
513
618
527
472
682
505
460
531
608
503
359
394
LT Debt
84,603
91,342
101,879
114,870
126,951
139,609
142,023
153,810
166,247
172,657
182,582
195,599
197,899
204,816
213,470
211,008
208,241
Total Equity
17.1
18.98
11.25
9.6
9.01
8.03
9.03
10.54
11.24
10.39
10.15
9.54
9.45
9.19
8.43
6.77
5.37
Return on Invested Capital (%)
10.48
9.89
11.61
11.12
10.4
9.78
9.86
10.85
11.45
11.19
10.41
9.97
9.94
9.96
4.77
1.75
4.13
Return on Capital (%)
10.81
10.11
11.71
11.17
10.45
9.82
9.89
10.9
11.5
11.24
10.45
9.99
9.97
10
4.78
1.74
4.14
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
343
- -
355
LT Borrowings
- -
- -
- -
LT Finance Leases
503
- -
394
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
74
- -
74
Market Capitalization
463,126
421,304
400,651

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
144,468
- -
135,971
Cash, Cash Equivalents & STI
65,745
- -
69,674
Accounts Receivable, Net
49,442
- -
32,973
Inventories
24,163
- -
30,653
Total Current Liabilities
46,423
- -
46,505
Payables & Accruals
- -
- -
- -
ST Debt
343
- -
355
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.26%
2.98%
-1.15%
Free Cash Flow
-60.56%
-137.57%
-175.27%
Net Income, GAAP
-6.22%
-21.68%
-63.68%
Sales/Revenue/Turnover
2.77%
2.03%
0.09%
Total Cash Common Dividend
8.03%
5.81%
1.97%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
36,485
36,651
41,323
51,141
165,600
2025
- -
- -
- -
- -
165,742
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
13.13
- -
- -
- -
135.42
2025
- -
- -
- -
- -
49.18
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
100.96
2025
- -
- -
- -
- -
102.95
2026
- -
- -
- -
- -
- -
Similar Companies
Solesence, Inc. Common Stock (SLSN)
Vinda International Holdings Limited (3331.HK)
BEAUTY GARAGE Inc. (3180.T)
Gr. Sarantis S.A. (SRTSF)
Colgate-Palmolive Company (0P59.L)
Zinzino AB (publ) (ZNZNF)
Business
Kobayashi Pharmaceutical Co., Ltd. manufactures and sells over-the-counter pharmaceuticals, quasi-drugs, deodorizing air fresheners, sanitary products, cosmetics, health foods, and daily necessities in Japan and internationally; offers specific brands including Ammeltz anti-inflammatory pain relief medicine, Dent effervescent denture cleaning agent, Ekitai Bluelet Okudake toilet bowl cleaner, Naicitol Chinese medicine, BreathCare oral breath freshener capsules, Netsusama cooling gel sheets, lens cleaners, oral hygiene products, and body warmers; and provides synthetic resin processed products, nutritional supplements via mail order, skincare items, and paper products. The company operates through domestic and international business segments targeting consumer health, personal care, and household markets primarily in Asia with headquarters in Osaka, Japan, where it was founded in 1886. It also engages in transportation, real estate management, advertising production, and asset management activities. In recent developments, Kobayashi Pharmaceutical faced a major health crisis in 2024 involving its red yeast rice supplements linked to reported deaths, prompting a CEO replacement in July 2024 and ongoing activist investor pressure from Oasis Management, which acquired a 5.2% stake, filed a shareholder derivative lawsuit in April 2025, and submitted a shareholder proposal in December 2025 to enhance governance and operational efficiency.